TY - JOUR
T1 - Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis
AU - Wootla, Bharath
AU - Watzlawik, Jens O.
AU - Stavropoulos, Nikolaos
AU - Wittenberg, Nathan J.
AU - Dasari, Harika
AU - Abdelrahim, Murtada A.
AU - Henley, John R.
AU - Oh, Sang Hyun
AU - Warrington, Arthur E.
AU - Rodriguez, Moses
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2016/6/2
Y1 - 2016/6/2
N2 - ABSTRACT: Introduction: Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the CNS and results in neurological disability. Existing immunomodulatory and immunosuppressive approaches lower the number of relapses but do not cure or reverse existing deficits nor improve long-term disability in MS patients. Areas Covered: Monogenic antibodies were described as treatment options for MS, however the immunogenicity of mouse antibodies hampered the efficacy of potential therapeutics in humans. Availability of improved antibody production technologies resulted in a paradigm shift in MS treatment strategies. In this review, an overview of immunotherapies for MS that use conventional monoclonal antibodies reactive to immune system and their properties and mechanisms of action will be discussed, including recent advances in MS therapeutics and highlight natural autoantibodies (NAbs) that directly target CNS cells. Expert Opinion: Recent challenges for MS therapy are the identification of relevant molecular and cellular targets, time frame of treatment, and antibody toxicity profiles to identify safe treatment options for MS patients. The application of monoclonal antibody therapies with better biological efficacy associated with minimum side effects possesses huge clinical potential. Advances in monoclonal antibody technologies that directly target cells of nervous system may promote the CNS regeneration field from bench to bedside.
AB - ABSTRACT: Introduction: Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the CNS and results in neurological disability. Existing immunomodulatory and immunosuppressive approaches lower the number of relapses but do not cure or reverse existing deficits nor improve long-term disability in MS patients. Areas Covered: Monogenic antibodies were described as treatment options for MS, however the immunogenicity of mouse antibodies hampered the efficacy of potential therapeutics in humans. Availability of improved antibody production technologies resulted in a paradigm shift in MS treatment strategies. In this review, an overview of immunotherapies for MS that use conventional monoclonal antibodies reactive to immune system and their properties and mechanisms of action will be discussed, including recent advances in MS therapeutics and highlight natural autoantibodies (NAbs) that directly target CNS cells. Expert Opinion: Recent challenges for MS therapy are the identification of relevant molecular and cellular targets, time frame of treatment, and antibody toxicity profiles to identify safe treatment options for MS patients. The application of monoclonal antibody therapies with better biological efficacy associated with minimum side effects possesses huge clinical potential. Advances in monoclonal antibody technologies that directly target cells of nervous system may promote the CNS regeneration field from bench to bedside.
KW - Multiple sclerosis
KW - clinical studies
KW - immunogenicity
KW - mAbs
KW - monoclonal antibodies
KW - safety
UR - http://www.scopus.com/inward/record.url?scp=84961219009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961219009&partnerID=8YFLogxK
U2 - 10.1517/14712598.2016.1158809
DO - 10.1517/14712598.2016.1158809
M3 - Review article
C2 - 26914737
AN - SCOPUS:84961219009
SN - 1471-2598
VL - 16
SP - 827
EP - 839
JO - Expert opinion on biological therapy
JF - Expert opinion on biological therapy
IS - 6
ER -